Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation

European Journal of Cancer

Volumn 57, Issue , 2016, Pages 78-86

  Tinhofer, I ^a,g   Budach, V ^a,g   Saki, M ^a,g   Konschak, R ^a,g   Niehr, F ^a,g   Johrens K ^g   Weichert, W ^e,h,i   Linge, A ^b,j   Lohaus, F ^b,j   Krause, M ^b,j,r   Neumann, K ^g   Endris, V ^e,h   Sak, A ^a,k   Stuschke, M ^a,k   Balermpas, P ^c,l   Rodel C ^c,l   Avlar, M ^d,m   Grosu, A L ^d,m   Abdollahi, A ^a,n   Debus, J ^a,n   Belka, C ^e,o   Pigorsch, S ^e,i   Combs, S E ^e,i,p   Monnich D ^f,q   Zips, D ^f,q   Baumann, M ^b,j,r   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b German Cancer Consortium (DKTK)   (Germany)

^c German Cancer Consortium (DKTK)   (Germany)

^d German Cancer Consortium (DKTK)   (Germany)

^e German Cancer Consortium (DKTK)   (Germany)

^f German Cancer Consortium (DKTK)   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k UNIVERSITY OF DUISBURG ESSEN   (Germany)

^l GOETHE UNIVERSITY   (Germany)

^m UNIVERSITY OF FREIBURG   (Germany)

ⁿ Helmholtz Zentrum Dresden Rossendorf   (Germany)

^o UNIVERSITY OF MUNICH   (Germany)

^p INSTITUTE OF EPIDEMIOLOGY   (Germany)

^q UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^r INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

more..

Author keywords

Adjuvant chemoradiation; Cisplatin; Head and neck cancer; Human papilloma virus; Mutation profiles

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; PROTEIN P53;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; EXON; FRAMESHIFT MUTATION; GENOMICS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MOUTH CARCINOMA; MULTIMODALITY CANCER THERAPY; NEXT GENERATION SEQUENCING; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; WART VIRUS; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DNA SEQUENCE; FEMALE; GENETICS; GENOTYPE; HEAD AND NECK NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PAPILLOMAVIRIDAE; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; VIRUS INFECTION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUTATION; PAPILLOMAVIRIDAE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS;

EID: 84958811509     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.01.003     Document Type: Article

References (37)

1. C.H. Chung, and M.L. Gillison Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications Clin Cancer Res 15 22 2009 6758 6762
2. N. Agrawal, M.J. Frederick, C.R. Pickering, C. Bettegowda, K. Chang, R.J. Li, and et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 Science 333 6046 2011 1154 1157
3. N. Stransky, A.M. Egloff, A.D. Tward, A.D. Kostic, K. Cibulskis, A. Sivachenko, and et al. The mutational landscape of head and neck squamous cell carcinoma Science 333 6046 2011 1157 1160
4. The Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas Nature 517 7536 2015 576 582
5. C.H. Chung, V.B. Guthrie, D.L. Masica, C. Tokheim, H. Kang, J. Richmon, and et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing Ann Oncol 26 6 2015 1216 1223
6. T.Y. Seiwert, Z. Zuo, M.K. Keck, A. Khattri, C.S. Pedamallu, T. Stricker, and et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas Clin Cancer Res 21 3 2015 632 641
7. L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A. Aparicio, S. Behjati, A.V. Biankin, and et al. Signatures of mutational processes in human cancer Nature 500 7463 2013 415 421
8. M. Lindenbergh-van der Plas, R.H. Brakenhoff, D.J. Kuik, M. Buijze, E. Bloemena, P.J. Snijders, and et al. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma Clin Cancer Res 17 11 2011 3733 3741
9. M.L. Poeta, J. Manola, M.A. Goldwasser, A. Forastiere, N. Benoit, J.A. Califano, and et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck N Engl J Med 357 25 2007 2552 2561
10. D.M. Neskey, A.A. Osman, T.J. Ow, P. Katsonis, T. McDonald, S.C. Hicks, and et al. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer Cancer Res 75 7 2015 1527 1536
11. F. Lohaus, A. Linge, I. Tinhofer, V. Budach, E. Gkika, M. Stuschke, and et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) Radiother Oncol 113 3 2014 317 323
12. A. de la Rochefordiere, M. Kamal, A. Floquet, L. Thomas, P. Petrow, T. Petit, and et al. PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy +/- cetuximab in cervical cancer patients Clin Cancer Res 21 11 2015 2530 2537
13. M.A. Hildebrandt, H. Yang, M.C. Hung, J.G. Izzo, M. Huang, J. Lin, and et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy J Clin Oncol 27 6 2009 857 871
14. O. Halevy, D. Michalovitz, and M. Oren Different tumor-derived p53 mutants exhibit distinct biological activities Science 250 4977 1990 113 116
15. R. Erber, C. Conradt, N. Homann, C. Enders, M. Finckh, A. Dietz, and et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer Oncogene 16 13 1998 1671 1679
16. H.D. Skinner, V.C. Sandulache, T.J. Ow, R.E. Meyn, J.S. Yordy, B.M. Beadle, and et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence Clin Cancer Res 18 1 2012 290 300
17. A.M. Gross, R.K. Orosco, J.P. Shen, A.M. Egloff, H. Carter, M. Hofree, and et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss Nat Genet 46 9 2014 939 943
18. L. Licitra, F. Perrone, P. Bossi, S. Suardi, L. Mariani, R. Artusi, and et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma J Clin Oncol 24 36 2006 5630 5636
19. N. Rivlin, R. Brosh, M. Oren, and V. Rotter Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis Genes Cancer 2 4 2011 466 474
20. R. Brosh, and V. Rotter When mutants gain new powers: news from the mutant p53 field Nat Rev Cancer 9 10 2009 701 713
21. P.A. Muller, and K.H. Vousden Mutant p53 in cancer: new functions and therapeutic opportunities Cancer Cell 25 3 2014 304 317
22. P. Perego, M. Giarola, S.C. Righetti, R. Supino, C. Caserini, D. Delia, and et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems Cancer Res 56 3 1996 556 562
23. A.R. Cuddihy, F. Jalali, C. Coackley, and R.G. Bristow WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells Mol Cancer Ther 7 4 2008 980 992
24. V.J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, and et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat Med 8 3 2002 282 288
25. E.M. Alexandrova, A.R. Yallowitz, D. Li, S. Xu, R. Schulz, D.A. Proia, and et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment Nature 523 7560 2015 352 356
26. L. Chin, J. Pomerantz, and R.A. DePinho The INK4a/ARF tumor suppressor: one gene-two products-two pathways Trends Biochem Sci 23 8 1998 291 296
27. A. Pacifico, and G. Leone Role of p53 and CDKN2A inactivation in human squamous cell carcinomas J Biomed Biotechnol 2007 3 2007 43418
28. J.B. McIntyre, J.S. Wu, P.S. Craighead, T. Phan, M. Kobel, S.P. Lees-Miller, and et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy Gynecol Oncol 128 3 2013 409 414
29. K.I. Abdul-Jalil, K.M. Sheehan, S. Toomey, J. Schmid, J. Prehn, A. O'Grady, and et al. The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study Ann Surg Oncol 21 8 2014 2642 2649
30. W.G. McKenna, R.J. Muschel, A.K. Gupta, S.M. Hahn, and E.J. Bernhard The RAS signal transduction pathway and its role in radiation sensitivity Oncogene 22 37 2003 5866 5875
31. E. Fokas, L. Conradi, C. Weiss, T. Sprenger, P. Middel, T. Rau, and et al. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study Int J Radiat Oncol Biol Phys 87 5 2013 992 999
32. M.P. Duldulao, W. Lee, R.A. Nelson, W. Li, Z. Chen, J. Kim, and et al. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma Ann Surg Oncol 20 7 2013 2166 2171
33. M.C. Garassino, M. Marabese, P. Rusconi, E. Rulli, O. Martelli, G. Farina, and et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer Ann Oncol 22 1 2011 235 237
34. A.K. Gupta, V.J. Bakanauskas, G.J. Cerniglia, Y. Cheng, E.J. Bernhard, R.J. Muschel, and et al. The Ras radiation resistance pathway Cancer Res 61 10 2001 4278 4282
35. T. Rieckmann, S. Tribius, T.J. Grob, F. Meyer, C.J. Busch, C. Petersen, and et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity Radiother Oncol 107 2 2013 242 246
36. R. Nagel, S.R. Martens-de Kemp, M. Buijze, G. Jacobs, B.J. Braakhuis, and R.H. Brakenhoff Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines Oral Oncol 49 6 2013 560 566
37. S.C. Raju, S.J. Hauff, A.J. Lemieux, R.K. Orosco, A.M. Gross, L.T. Nguyen, and et al. Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma Oral Oncol 51 5 2015 470 475